Journal of Nutrition,Fasting and Health

Journal of Nutrition,Fasting and Health

Effects of Camel Milk on Antioxidant Activity in Rats with Valproic Acid-induced Autism

Document Type : Research Paper

Authors
Sahar Heydari 1
Ali Mahmoudi 2
Bahareh Amin 3
Akbar Pejhan 1
Seyed Jamal Mirmoosavi 4
Omid Gholami 1
Mohammad Mohammad-Zadeh 5
1 Department of Physiology and Pharmacology, Faculty of Medicine, Sabzevar University of Medical Sciences, Iran
2 Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Iran
3 Associate Professor of Department of Physiology and Pharmacology, Faculty of Medicine, Sabzevar University of Medical Sciences, Iran
4 Department of Traditional Medicine, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
5 Psychiatry & Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
10.22038/jnfh.2021.55516.1321
Abstract
Introduction: Autism spectrum disorder refers to a wide range of nervous system disorders. Autistic patients often have a defective antioxidant defense system and manifest symptoms of impaired cognitive interaction. Camel milk has numerous beneficial nutrients and has been used in the treatment of autism. The present study aimed to investigate the effects of camel milk on the antioxidant activity and enzymes of autistic rats. Methods: Pregnant rats were intraperitoneally injected on embryonic day 12.5 with valproic acid (VPA; 500 mg/kg) to induce an autistic state. In addition, 18 male offspring rats were injected with risperidone (0.2 mg/kg) three times per week. Six of these cases were fed daily with raw camel milk (10 ml/kg), and six others were fed with pasteurized camel milk for 42 days. Social interaction and repetitive behaviors were measured using the Y-maze based on catalase (CAT) activity, glutathione (GSH) level, and superoxide dismutase (SOD) activity at the outset and after the treatment period. Results: Behavioral symptoms (impaired social interaction and repetitive behaviors) were evident after VPA administration. After receiving treatment, impaired social interaction and repetitive behaviors significantly improved in the autistic rats (P<0.01). In addition, VPA enhanced the oxidative stress status in the biochemical tests (P<0.001), and camel milk increased CAT activity (P<0.001), GSH level (P<0.05), and SOD activity (P<0.0001). Conclusion: According to the results, camel milk could recover the VPA-induced impairment of social interaction and repetitive behaviors in the autistic rats and improve the defects in their antioxidant defense system.
Keywords
Antioxidant enzyme
Autism
Behavior test
VPA
1. Jones EJ, Gliga T, Bedford R, Charman T, Johnson MH. Developmental pathways to autism: a review of prospective studies of infants at risk. Neurosci Biobehav Rev. 2014;39(100):1-33.
2.Bromley RL, Mawer G, Clayton-Smith J, Baker GA. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology. 2008;71(23):1923-4.
3.Yenkoyan K, Grigoryan A, Fereshetyan K, Yepremyan D. Advances in understanding the pathophysiology of autism spectrum disorders. Behavioural brain research. 2017;331:92-101.
4.Rodier PM. Animal model of autism based on developmental data. Ment Retard Dev Disabil Res Rev. 1996;2(4):249-56.
5.Roullet FI, Lai JK, Foster JA. In utero exposure to valproic acid and autism--a current review of clinical and animal studies. Neurotoxicol Teratol . 2013;36:47-56.
6.Karl T, Pabst R, von Hörsten S. Behavioral phenotyping of mice in pharmacological and toxicological research. Exp Toxicol Pathol. 2003;55(1):69-83.
7.Mirza R, Sharma B. Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. Brain Res Bull. 2019;147:36-46.
8.Stepanova E, Dowling S, Phelps M, Findling RL. Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialogues Clin Neurosci. 2017;19(4):395-402.
9.Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism.  Prog Neuropsychopharmacol Biol Psychiatry. 1993;17(5):765-74.
10.Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;13:757-72.
11.Rose S, Melnyk S, Pavliv O, Bai S, Nick TG, Frye RE, et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl. Psychiatry. 2012;2(7):e134.
12.James SJ, Melnyk S, Jernigan S, Pavliv O, Trusty T, Lehman S, et al. A functional polymorphism in the reduced folate carrier gene and DNA hypomethylation in mothers of children with autism. American journal of medical genetics Part B, Neuropsychiatric genetics.. 2010;153b(6):1209-20.
13.Manivasagam T, Arunadevi S, Essa MM, SaravanaBabu C, Borah A, Thenmozhi AJ, et al. Role of Oxidative Stress and Antioxidants in Autism. Advances in neurobiology. 2020;24:193-206.
14.Russo AJ. Decreased serum Ou/Zn sOD in children with Autism. Nutr Metab Insights. 2009;2:NMI.S3733.
15.Al-Ayadhi LY, Elamin NE. Camel milk as a potential therapy as an antioxidant in autism spectrum disorder (ASD). Evid Based Complement Alternat Med. 2013;2013:602834.
16.Yagil R. Camel milk and its unique anti-diarrheal properties. Isr Med Assoc J. 2013;15(1):35-6.
17.Mohamed HE, Mousa HM, Beynen AC. Ascorbic acid concentrations in milk from Sudanese camels. J Anim Physiol Anim Nutr. 2005;89(1-2):35-7.
18.Ambali SF, Idris SB, Onukak C, Shittu M, Ayo JO. Ameliorative effects of vitamin C on short-term sensorimotor and cognitive changes induced by acute chlorpyrifos exposure in Wistar rats. Toxicol Ind Health. 2010;26(9):547-58.
19. Clutton-Brock J. A natural history of domesticated mammals: Cambridge University Press; 1999.
20.Saltanat H, Li H, Xu Y, Wang J, Liu F, Geng XH. [The influences of camel milk on the immune response of chronic hepatitis B patients]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. 2009;25(5):431-3.
21.Shabo Y, Yagil R. Etiology of autism and camel milk as therapy. Int J Disabil Hum Dev. 2005;4(2):67.
22.Adams CM. Patient report: autism spectrum disorder treated with camel milk. Glob Adv Health Med. 2013;2(6):78-80.
23.Hara Y, Ago Y, Higuchi M, Hasebe S, Nakazawa T, Hashimoto H, et al. Oxytocin attenuates deficits in social interaction but not recognition memory in a prenatal valproic acid-induced mouse model of autism. Horm Behav. 2017;96:130-6.
24.Wang L, Almeida LE, Spornick NA, Kenyon N, Kamimura S, Khaibullina A, et al. Modulation of social deficits and repetitive behaviors in a mouse model of autism: the role of the nicotinic cholinergic system. Psychopharmacology. 2015;232(23):4303-16.
25.Merali Z, Presti-Torres J, Mackay JC, Johnstone J, Du L, St-Jean A, et al. Long-term behavioral effects of neonatal blockade of gastrin-releasing peptide receptors in rats: similarities to autism spectrum disorders. Behav Brain Res. 2014;263:60-9.
26.Madesh M, Balasubramanian KA. Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide. Indian J Biochem Biophys. 1998;35(3):184-8.
27.Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-6.
28.Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70-7.
29.Hamzawy MA, El-Ghandour YB, Abdel-Aziem SH, Ali ZH. Leptin and camel milk abate oxidative stress status, genotoxicity induced in valproic acid rat model of autism. Int J Immunopathol Pharmacol. 2018;32:2058738418785514.
30.Silverman JL, Pride MC, Hayes JE, Puhger KR, Butler-Struben HM, Baker S, et al. GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2015;40(9):2228-39.
31.Moy SS, Nadler JJ, Perez A, Barbaro RP, Johns JM, Magnuson TR, et al. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav. 2004;3(5):287-302.
32.Schneider T, Turczak J, Przewłocki R. Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: issues for a therapeutic approach in autism. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006;31(1):36-46.
33.Ishola IO, Balogun AO, Adeyemi OO. Novel potential of metformin on valproic acid-induced autism spectrum disorder in rats: involvement of antioxidant defence system. Fundam Clin Pharmacol. 2020;34(6):650-61.
34.Kumar H, Sharma BM, Sharma B. Benefits of agomelatine in behavioral, neurochemical and blood brain barrier alterations in prenatal valproic acid induced autism spectrum disorder. Neurochem Int. 2015;91:34-45.
35.Al-Amin MM, Rahman MM, Khan FR, Zaman F, Mahmud Reza H. Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism. Behav Brain Res. 2015;286:112-21.
36.Hara Y, Ago Y, Taruta A, Hasebe S, Kawase H, Tanabe W, et al. Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice. Psychopharmacology. 2017;234(21):3217-28.
37.Kawanai T, Ago Y, Watanabe R, Inoue A, Taruta A, Onaka Y, et al. Prenatal Exposure to Histone Deacetylase Inhibitors Affects Gene Expression of Autism-Related Molecules and Delays Neuronal Maturation. Neurochem Res. 2016;41(10):2574-84.
38.Sharp JA, Brennan AJ, Polekhina G, Ascher DB, Lefevre C, Nicholas KR. Dimeric but not monomeric α-lactalbumin potentiates apoptosis by up regulation of ATF3 and reduction of histone deacetylase activity in primary and immortalised cells. Cell Signal. 2017;33:86-97.
39.Banerjee A, García-Oscos F, Roychowdhury S, Galindo LC, Hall S, Kilgard MP, et al. Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism. Int J Neuropsychopharmacol. 2013;16(6):1309-18.
40.Fleming SA, Mudd AT, Hauser J, Yan J, Metairon S, Steiner P, et al. Dietary oligofructose alone or in combination with 2′-fucosyllactose differentially improves recognition memory and hippocampal mrna expression. Nutrients. 2020;12(7):1-17.
41.Caiati MD, Cherubini E. Fluoxetine impairs GABAergic signaling in hippocampal slices from neonatal rats. Front Cell Neurosci. 2013(APR).
42.Bernal-Morales B, Cueto-Escobedo J, Guillén-Ruiz G, Rodríguez-Landa JF, Contreras CM. A fatty acids mixture reduces anxiety-like behaviors in infant rats mediated by GABAA receptors. BioMed Res Int. 2017;2017.
43.Matsuo K, Yabuki Y, Fukunaga K. 5-aminolevulinic acid inhibits oxidative stress and ameliorates autistic-like behaviors in prenatal valproic acid-exposed rats. Neuropharmacology. 2020;168:107975.
44.Win-Shwe TT, Nway NC, Imai M, Lwin TT, Mar O, Watanabe H. Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism. J Toxicol Sci. 2018;43(11):631-43.
45.Abd-Elhakim YM, El-Sharkawy NI, Mohammed HH, Ebraheim LLM, Shalaby MA. Camel milk rescues neurotoxic impairments induced by fenpropathrin via regulating oxidative stress, apoptotic, and inflammatory events in the brain of rats. Food Chem Toxicol. 2020;135:111055.
46.Ibrahim HM, Mohammed-Geba K. Camel milk exosomes modulate cyclophosphamide-induced oxidative stress and immuno-toxicity in rats. 2019;10(11):7523-32.
47.Zibaee S, Hosseini SM, Yousefi M, Taghipour A, Kiani MA, Noras MR. Nutritional and Therapeutic Characteristics of Camel Milk in Children: A Systematic Review. Electron Physician. 2015;7(7):1523-8.
48.Malaguarnera M, Khan H, Cauli O. Resveratrol in autism spectrum disorders: Behavioral and molecular effects. Antioxidants. 2020;9(3).
49.Stojković T, Radonjić NV, Velimirović M, Jevtić G, Popović V, Doknić M, et al. Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(1):192-9.
Journal of Nutrition,Fasting and Health
Volume 9, Issue 2
Spring 2021
Pages 160-170

  • Receive Date 08 February 2021
  • Revise Date 16 March 2021
  • Accept Date 04 April 2021